Compare Digital Realty Trust, Inc. (DLR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs GeneDx Holdings Corp — how do they compare? Digital Realty Trust, Inc. trades at $176.26 (market cap $66.95B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Digital Realty Trust, Inc. is far larger — about 32.8× GeneDx Holdings Corp's market cap, and Digital Realty Trust, Inc. pays a 2.7% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and GeneDx Holdings Corp for 19 Days on average.
| DLR | WGS | |
|---|---|---|
Market Cap | $66.95B | $2.04B |
Volume | 1,766,660 | 659,215 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $167.51 |
52-Week Low | $147.93 | $34.51 |
Typical Hold Time | 94 Days | 19 Days |
Enterprise Value | $85.67B | $2.08B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $176.07, down 4.65% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamental momentum, with Q2 2026 EPS beating expectations at $1.21 versus $0.4829, and revenue growth from $6.11B in 2025 to a projected $6.8B in 2026. Recent news highlights expansion in AI infrastructure, including a collaboration with Blackfuel and a new Los Angeles cable landing station, positioning the company to capitalize on data center demand.
The outlook for DLR is positive, driven by robust AI-driven demand and a record backlog, though high valuation multiples like a P/E of 88.03 pose a risk if growth slows. Analyst consensus is strongly bullish with a $222.35 price target, but investors face risks from significant capital expenditures and debt levels.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
